Role of microRNA in chronic lymphocytic leukemia onset and progression

Balatti, Veronica; Pekarky, Yuri; Croce, Carlo M.

doi:10.1186/s13045-015-0112-x

Cited by 69 publications

(54 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…miRNAs are a subset of small noncoding RNAs that control gene expression in a site-specific manner (15). Accumulating evidence has identified the distinct expression patterns and biological functions of miRNAs in biological processes, including cell differentiation, apoptosis, and metabolism (16). Overexpression of miR-217 inhibited cellular proliferation and enhanced cell chemosensitivity to doxorubicin by the cell apoptosis pathway in AML cells (17).…”

mentioning

confidence: 99%

Role of Circular RNA DLEU2 in Human Acute Myeloid Leukemia

Wen

Han

et al. 2018

Molecular and Cellular Biology

View full text Add to dashboard Cite

In the current study, we were interested in exploring the molecular mechanism of circular RNA DLEU2 (circRNA-DLEU2) (hsa_circ_0000488) and microRNA 496 (miR-496), as well as PRKACB, in human acute myeloid leukemia (AML) cell activities. The RNA expression levels of circRNA-DLEU2, hsa-miR-496, and PRKACB were assessed by quantitative real-time PCR (qRT-PCR). The proliferation and apoptosis abilities of the cells were determined by CCK8 assay and flow cytometry analysis. Target relationships between circRNA-DLEU2 and miR-496, as well as PRKACB, were analyzed by luciferase reporter assay and probe assay. Immunoblotting assays were used to detect the protein expression level of PRKACB. We also did experiments to observe tumor formation after overexpression of circRNA-DLEU2. Our data showed that circRNA-DLEU2 was upregulated in AML tissues and cells, which promoted AML cell proliferation and inhibited cell apoptosis. circRNA-DLEU2 promoted AML tumor formation miR-496 was inhibited by circRNA-DLEU2 and was downregulated in AML tissues. circRNA-DLEU2 inhibited miR-496 expression and promoted PRKACB expression. miR-496 antagonized the effects of PRKACB on MOLM-13 cell proliferation and apoptosis. Collectively, circRNA-DLEU2 accelerated human AML by suppressing miR-496 and promoting PRKACB expression.

show abstract

mentioning

confidence: 99%

Role of Circular RNA DLEU2 in Human Acute Myeloid Leukemia

Wen

Han

et al. 2018

Molecular and Cellular Biology

View full text Add to dashboard Cite

show abstract

“…MicroRNAs (miRs) are a class of noncoding single-stranded RNA molecules of 21-23 nucleotides, which bind to 3′untranslated region (UTR) of the target messenger RNA (mRNA) and trigger either mRNA degradation or inhibition of translation depending on the degree of complementarity between miR and its target [1]. Since the first description of the loss of miR-15/16 in chronic lymphocytic leukemia (CLL) [2], studies have reported the deregulation of miRs in a variety of hematopoietic and solid tumors, functioning as either oncogenes or tumor suppressors regarding context and cell types [3][4][5].…”

mentioning

confidence: 99%

miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11

Zhou

Feng

Wang

et al. 2018

Experimental Hematology

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) is an aggressive lymphoid malignancy characterized by cytogenetic aberration of t(11;14), although it is not the prerequisite. Until now, the pathogenesis of MCL has not been fully interpreted. Our current study showed that microRNA (miR)-223 was downregulated in purified CD19 lymphocytes from MCL patients (n = 21) compared with that of healthy donors (n = 20). In addition, patients with a high-risk Mantle Cell Lymphoma International Prognostic Index (MIPI) score, elevated lactate dehydrogenase, and Eastern Cooperative Oncology Group performance status >2 were more likely to have much lower miR-223 expression. Furthermore, low miR-223 expression predicted inferior overall survival regardless of treatment in our cohort of 21. To explore the role of miR-223 in MCL, we constructed an ectopic miR-223 MCL cell line and revealed that miR-223 inhibited cell proliferation and promoted G/G accumulation and cell apoptosis. A database search showed that SOX11, a crucial transcription factor in MCL, is the putative target of miR-223. In support of this, we observed a much lower level of SOX11 protein in miR-223-overexpressing cells than in parental cells. Further, the luciferase reporter assay confirmed that miR-223 at the posttranscriptional level suppressed the wild-type 3'-untranslated region of SOX11 but not the mutated one. Finally, miR-223 was found to be negatively correlated with the mRNA level of SOX11 in clinical samples. Our work demonstrates for the first time that miR-223 is repressed and correlated with high-risk clinical features in MCL, which provides a potential molecule to target to optimize MCL management.

show abstract

“…It is estimated that the human genome is able to produce two thousands of different miRNAs, which regulate the expression of approximately 95% of protein-coding genes, thus controlling the activity and function of key signaling pathways and cellular processes, including cell proliferation, apoptosis, cell differentiation, and response to hypoxia [4]. miRNAs can function either as oncogenes or tumor suppressors and some of them play a particular role in papillary thyroid cancer [5]. From a clinical perspective, particular miRNAs can be exploited as diagnostic and/or prognostic biomarkers in papillary thyroid cancer [6].…”

Section: Introductionmentioning

confidence: 99%

“…During the last ten years, scientists have put intensive efforts on deciphering the molecular impact of miRNA expression in thyroid cancer. A great number of miRNAs regulate the expression of important genes, assisting in the elucidation of molecular aspects of thyroid cancer onset and/or progression [5].…”

Section: Introductionmentioning

confidence: 99%

Identification of a Novel, Diagnostic microRNA Signature in Papillary Thyroid Cancer

Poulios¹,

Zografos²,

Balafouta³

et al. 2018

J Med Surg Pathol

View full text Add to dashboard Cite

Diagnosis is based on ultrasound and fine needle aspiration pathological findings. Screening asymptomatic people as well as those being at normal risk for thyroid cancer is not recommended. "Molecular signatures" consisting of miRNAs could be accounted for as promising diagnostic and/or prognostic biomarkers for different human malignancies, including thyroid cancer. MicroRNA molecules, being stable in blood and urine, are ideal components of molecular signatures. In this study, we sought to identify a molecular signature that could be used to diagnose papillary thyroid cancer with high sensitivity and specificity. For this purpose, we performed miRNA-seq to identify and quantify miRNAs showing high difference in their expression levels in serum of patients with papillary thyroid cancer and other diseases of thyroid and/or normal population. Validation was performed using real-time PCR. Using this approach, we found eight miRNAs being significantly over-or underexpressed in papillary thyroid cancer tissues compared to their normal counterparts (normal thyroid tissues): miR-144-3p, miR-622, miR-361-5p, miR-146a-3p, miR-340-5p, miR-199a-5p, miR-335-5p, and miR-129-5p. Five out of these eight miRNAs are also significantly over-or under-represented in blood serum of patients with papillary thyroid cancer. In conclusion, our study shows, for the first time, that a molecular signature consisting of miR-144-3p, miR-146a-3p, miR-340-5p, miR-199a-5p and miR-335-5p, is able to diagnose with high sensitivity and specificity papillary thyroid cancer in patients' blood serum.

show abstract

Role of microRNA in chronic lymphocytic leukemia onset and progression

Cited by 69 publications

References 42 publications

Role of Circular RNA DLEU2 in Human Acute Myeloid Leukemia

Role of Circular RNA DLEU2 in Human Acute Myeloid Leukemia

miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11

Identification of a Novel, Diagnostic microRNA Signature in Papillary Thyroid Cancer

Contact Info

Product

Resources

About